Q32 Bio Inc. (QTTB) Common Equity (2017 - 2026)

Q32 Bio has reported Common Equity for 10 years, with the latest figure at $105.9 million in Q2 2026.

• On a quarterly basis, Common Equity rose 965.59% year-over-year to $105.9 million in Q2 2026; TTM through Jun 2026 was $105.9 million, a 965.59% increase from a year earlier, with the FY2025 full-year figure at $42.0 million, up 640.33% from the prior year.
• Common Equity was $105.9 million for Q2 2026 at Q32 Bio, up from $46.3 million in the prior quarter.
• The five-year high for Common Equity was $266.3 million in Q1 2022, with the low at -$182.9 million in Q4 2023.
• Average Common Equity over 5 years is $12.9 million, with a median of $12.0 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Common Equity plunged 200.84% in 2025, then soared 1253.79% in 2026.
• Over 5 years, Common Equity stood at -$130.7 million in 2022, then tumbled by 39.94% to -$182.9 million in 2023, then soared by 103.1% to $5.7 million in 2024, then jumped by 640.33% to $42.0 million in 2025, then jumped by 152.07% to $105.9 million in 2026.
• The last three Common Equity figures came in at $105.9 million (Q2 2026), $46.3 million (Q1 2026), and $42.0 million (Q4 2025), per Business Quant data.